LoQus23 Therapeutics appoints Cyrus Mozayeni MD to Chair of the Board of Directors
Published on 08/07/2025 at 18:04 | prnewswire.co.uk
Dr Mozayeni brings deep experience in biotech corporate strategy and business development Appointment follows successful £35 million Series A fundraise at the end of 2024 to take its MSH3 inhibitors to treat Huntington's disease into the clinicView original content:https://www.prnewswire.co.uk/news-releases/loqus23-therapeutics-appoints-cyrus-mozayeni-md-to-chair-of-the-board-of-directors-302378149.html
en | boerse | 67978099 |
